Objective: To explore factors associated with adherence to antihypertensive drugs overall (therapy adherence) and to particular classes (class adherence) in hypertensive patients.
INTRODUCTION
H ypertension is a highly prevalent condition in the United Kingdom (UK) with an estimated prevalence of 13.7% [1] . Antihypertensive drugs have been shown to reduce the risk of cardiovascular complications, premature mortality [2] , and achieve cost-savings [3] in people with hypertension. Nevertheless, suboptimal control of blood pressure (BP) has been consistently reported in population-based surveys of hypertension management worldwide [4, 5] .
Patients' poor adherence to antihypertensive drugs is considered one of the key contributing factors to suboptimal BP control [6] . Long-term adherence to antihypertensive therapy is crucial to achieve and maintain optimal BP control [7] . Reported adherence to antihypertensive drugs varies from 28 to 78% [8, 9] , attributed mostly to differences in study populations, types of medications being considered, study designs, follow-up time, and definitions and measurement of adherence.
Poor adherence to antihypertensive drugs is associated with increased cardiovascular events and hospitalizations with subsequently high costs and healthcare resources utilization [10, 11] . In England, the estimated potential cost of the health gains foregone as a result of nonadherence to antihypertensive drugs is about £390 million per annum [12] . It was also estimated that over £100 million per annum would be saved if 80% of people with hypertension were adherent to their medications [12] .
Understanding factors associated with adherence is crucial for patients, and healthcare professionals and providers. Previous studies have found associations between adherence to antihypertensive drug therapy and factors such as patients' age, sex, comorbidity, and type of antihypertensive drug class [8, 9] ; however, the joint impacts of these factors have not been evaluated together in a single cohort.
Most studies assessed adherence to antihypertensive drug classes in patients with newly-diagnosed hypertension [13] . Patients with preexisting hypertension are expected to have different medication-taking behaviours compared with newly-diagnosed patients [13] . The impact of switching from one antihypertensive drug class to another on a patient's adherence to overall antihypertensive drug therapy (therapy adherence) as well as to a particular antihypertensive drugs class (class adherence) has not been widely studied [8, 9] . Assessing adherence to individual antihypertensive drug classes without considering adherence to overall antihypertensive drug therapy limits the applicability of research findings from most previous studies as the majority of hypertensive patients are prescribed more than one antihypertensive drug class for their BP control [2] . Many studies have transformed adherence into a binary variable, using a cut-off point of 80%. Furthermore, a simple binary measure for adherence [8, 14] assumes patients over a wide range of adherence values [proportion of days covered (PDC) 0-80%] to have same medicationtaking behaviour and thus may potentially misclassify/misjudge a patient's adherence behaviour.
These factors limit the application and generalizability of previous study results to patient medicine-taking behaviour in real practice. To add to what is known about adherence in hypertension, this study assessed the association between patient characteristics and adherence to both overall antihypertensive therapy and individual drug classes by applying a robust analytical method to analyse adherence as a continuous variable in patients with both newly diagnosed and preexisting primary hypertension as an approach to produce more accurate and generalizable findings.
METHODS

Study design and data source
The current retrospective cohort study used data from the UK Clinical Practice Research Datalink (CPRD) database [15] from April 2006 to March 2013, as it was the most updated date for the availability of CPRD data at the time of the study. CPRD is a primary care database containing longitudinal electronic clinical data of more than 13.7 million patients including information about patients' demographics, medical conditions, diagnoses, prescribed medications, vaccination and laboratory tests. By March 2015, CPRD included 5.4 million active patients from 685 primary care practices across the UK [16] ; it covers about 8.5% of the UK population and is considered to be broadly representative in terms of patient and practice characteristics [17] .
This study protocol was approved by the Independent Scientific Advisory Committee of CPRD database (protocol number 13_150).
Study cohort
Adults (!18 years old) with a diagnosis of primary hypertension and at least two antihypertensive drug prescriptions after the diagnosis date during the study period were included in this study. Included patient needed to have at least 1 year of CPRD records before and after the date of their first-ever antihypertensive drug prescription (index date) during the study period. Sporadic users who were prescribed only one antihypertensive prescription were excluded [13] . To ensure that treating hypertension is at least one of the potential indications of the prescribed antihypertensive drugs, participants were required to have their antihypertensive drugs prescribed on or after their hypertension diagnosis date.
Patients with history of cardiovascular diseases (CVDs) prior to the index date were excluded because the presence of CVDs may affect the choice of antihypertensive drugs (indication bias) and patients' medication-taking behaviours (i.e. higher adherence as they are more willing to follow medical instructions) [18, 19] . Patients who were initiated on multiple antihypertensive drugs (either as fixed-dose combination or multiple pills) on the index date were also excluded as it was not possible to assign patients into a particular antihypertensive drug class which, in turn, conflicted with the study's objective of measuring a patient's adherence to any antihypertensive drug therapy. Indeed, these patients have often been excluded from previous adherence studies as they were reported to be at high risk of hypertension-related complications, having higher BP value and hence would have different medication-taking behaviours [2, 20, 21] .
Measurement of adherence
Individuals in the cohort were followed from the index date to the earliest of study end date, patient transferred out of the dataset (e.g., left the practice), or patient's death; during this period, all antihypertensive prescriptions issued were retrieved, and the duration of each prescription was calculated. Antihypertensive drugs were further divided into six classes: angiotensin-converting enzyme inhibitors (ACEIs), calcium-channel blockers (CCBs), diuretics, AT1 blockers (ARBs), beta-blockers, and 'Others' (including vasodilators, centrally acting drugs, and alphablockers).
A commonly used adherence measure [22] , PDC, was used as a 'proxy' for adherence in this study, and both antihypertensive 'therapy adherence' and 'class adherence' were measured. Individual patients' adherence to any antihypertensive drug therapy (PDC for therapy adherence) during the study period was calculated by dividing the total number of days covered with any antihypertensive drug by the number of days in the follow-up period [22] . Likewise, adherence to a specific antihypertensive drug class (PDC for class adherence) in each prescribing episode of a class was calculated by dividing the total number of days covered with an antihypertensive class by the number of days in a prescribing episode of that class.
The prescribing episode for a class was the duration when a patient was consecutively prescribed with the same antihypertensive drug class, starting from the date of a patient's first-ever prescription of the class during the study period to the final date covered by the antihypertensive class. Multiple episodes can be identified in one patient's follow-up period, as patients may discontinue or switch to other drug classes. Townsend deprivation score [23] ranging from one to five (one being least deprived and five most deprived) was used a proxy for individual patients' SES. Individual's comorbidity status was measured by the Charlson comorbidity index (CCI) [24] . Hypertension status, that is, preexisting (prevalent) or newly diagnosed (incident) hypertension, was judged by whether a patient had any hypertension-related diagnosis codes in the year prior to the first hypertension diagnosis code identified during the study period [25] .
Study covariates
Similarly, antihypertensive drug use status, that is preexisting (prevalent) or new (incident) users of a specific antihypertensive class was judged by whether any antihypertensive class was issued in the year prior to the index prescription date identified during the episode. Switching was defined as stopping the initial antihypertensive class and starting another class.
Data analysis
Descriptive statistics were used to describe patient-related factors at baseline. Mean with SD and median with interquartile range (IQR) were used to present normally and nonnormally distributed continuous variables, respectively; proportion was used to present categorical variables. The association between individual patient characteristics and the nonnormally distributed PDC was first tested in nonparametric univariate analyses, including Spearman's rank correlation test for continuous variables (age and follow-up time), Wilcoxon rank-sum (Mann-Whitney), and KruskalWallis tests for binary and categorical variables.
The influence of all study covariates on therapy and class adherence was assessed by using two generalized linear models (GLMs) with gamma family and log-link function, with the dependent variable as 'PDC for antihypertensive drug therapy' and 'PDC for each episode of antihypertensive classes', respectively. The results were presented as regression coefficients and 95% confidence interval (95% CI). The models' goodness of fit, in terms of the appropriateness of the chosen family and link function, was checked using the modified Park test [26] and Pregibon link test [27] .
RESULTS
Baseline characteristics
Overall, 176 835 adults with primary hypertension were included in this study with 371 605 prescribing episodes of the six antihypertensive classes identified during the follow-up period. The mean age of patients at baseline was 60.8 AE 13.6 years, 55.6% (n ¼ 98 320) were women, 53.4% (n ¼ 94 430) were newly diagnosed hypertensive patients, and 51.0% (n ¼ 90 186) were new users of antihypertensive drugs. The median follow-up duration was 5.3 (IQR: 3.1, 6.5) years. Of the 371 605 prescribing episodes, the most commonly prescribed class episodes were ACEIs (29.7%) and CCBs (25.1%). Patients' characteristics and drug-use status were significantly different across the episodes of six antihypertensive classes ( Table 1) .
Proportion of days covered
Both individual patients' PDCs for antihypertensive drug therapy overall ( Fig. 1) and PDCs for antihypertensive class in each episode ( Fig. 2) were not normally distributed. Although the median PDC was 93.3 (IQR: 47.3%, 100%) and 98.3% (IQR: 86.5%, 100%) for therapy and class adherence, respectively, 20.0% of patients' therapeutic adherence and 38.4% of prescribing episodes' class adherence were suboptimal (PDC < 80%). Mean therapy and class adherence was 87 AE 22.2 and 73 AE 33.8%, respectively.
Univariate analyses of factors influencing adherence
The univariate analyses demonstrated that all the covariates were significantly associated with PDC for therapy adherence in the study cohort and with PDC for class adherence in each episode (Table 2) . Patients who were initiating antihypertensive therapy on CCBs had the highest PDC for therapy adherence (median: 98.6%, IQR: 86.5%, 100%). On the other hand, the median PDC for class adherence in the prescribing episodes of ARBs (median: 97.4%, IQR: 74.2%, 100%) was the highest amongst all antihypertensive drug classes, followed by ACEIs (median: 95.7%, IQR: 51.3%, 100%).
Both higher therapy and class PDCs were associated with increasing age, lower deprivation, prevalent drug users, and higher comorbidity index (CCI ! 2). Male sex, being preexisting hypertensive patient, was associated with higher PDCs in the episodes of antihypertensive classes but lower PDCs for patients' overall therapy adherence. Switching between antihypertensive drug classes was also associated with lower PDC for therapy adherence.
Multivariate analyses of factors influencing adherence
The results from the GLM analysis indicated that all the patient characteristics were independent factors for both patients' adherence to antihypertensive therapy and to a specific drug class in each episode (Table 3) .
Being female sex, having preexisting hypertension, previous utilization of antihypertensive medicines, and older age were associated with higher PDC for patients' antihypertensive therapy; on the other hand, higher deprivation index, high comorbidity scores (CCI ! 2), and switching of antihypertensive drug class were associated with lower PDC of patients' antihypertensive therapy. For the patients who were initiated with ACEIs and ARB as the index drug class during the study period, PDCs for therapy adherence significantly increased by 4 and 3% (P < 0.001), respectively.
Similarly, preexisting hypertension, preexisting antihypertensive drug user, and older age were also associated with a higher PDC for class adherence in each episode; on the other hand, being female sex, higher deprivation index, and high comorbidity scores (CCI ! 2) were associated with lower a PDC for class adherence. Comparing between different antihypertensive drug classes, the highest PDC was in the episodes started from ARBs (13%, P < 0.001), followed by ACEIs (8%, P < 0.001); and the PDC for class categories 'Others' was the lowest (11%, P < 0.001).
Both class and therapy PDCs significantly changed over patients' follow-up time. There was a significant declining trend in class PDC across follow-up time categories with an average decline of 1.4% for each year increase in follow-up time, whereas for therapy PDC, although there was an average increase of patients' adherence to any antihypertensive therapy by 0.7% for each year increase in follow-up time, the effects across follow-up time categories were different.
The fitted multivariate GLM regression models can predict both the mean therapy and class PDCs for any patient with a particular set of characteristics included in the model. For instance, the predicted mean PDC of diuretics in the episodes for a 50-year-old female patient, with a deprivation index of two and comorbidity score at least two, having diuretics as the index antihypertensive drug class, being a new antihypertensive drug user, having preexisting hypertension, and 4 years of follow-up time, is 67.7% (95% CI: 66.8, 69.5%).
DISCUSSION
Main findings
The current study assessed adherence to both individual antihypertensive drug classes and overall antihypertensive therapy using longitudinal data over a 7-year period. To our knowledge, this study is the only study that has collectively analysed adherence, as a continuous variable, to both antihypertensive drug classes and overall therapy over a long period in a population of both new and existing hypertensive patient, thus providing generalizable findings by overcoming the aforementioned limitations of the previous studies. Although no similar studies were found for direct comparison of the study findings, the findings were compared with results from various studies. Overall findings are not dissimilar to these earlier studies, but now we can more confidently describe adherence behaviours in both incident and prevalent populations and better understand the relationship between individual drug class and overall therapy adherence.
The median PDC at first glance may appear generally high, but the other summary measures, despite their limitations (such as mean and proportion with PDC < 80%), demonstrated a suboptimal PDC level that is comparable with other adherence studies [22] . The overall mean PDC for antihypertensive drug class in each prescribing episode was 73%, and about 40% episodes had PDC less than 80%. Although these results are comparable with the mean class adherence of 67% and PDC less than 80% of 36% reported by a systematic review of 139 observational studies of adherence to antihypertensive drug classes [28] , the follow-up time over which adherence was measured in the systematic review was only 1 year which provided limited insights into the dynamic nature of adherence beyond 1 year. However, the current study examined adherence over 7 years and has provided deeper understanding of patients' behaviours in taking their antihypertensive medications. Class adherence declined steadily, unlike therapy adherence that showed a different pattern consisting of significant reduction in the early course of therapy (>2-3 years), followed by insignificant change (>3-5 years) then a significant increase afterward (>5 years).
Furthermore, a recent observational study, assessing association between patients' characteristics and adherence 
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Factors associated with patients adherence
Medications and clinically related factors Type of antihypertensive drug class was a significant predictor for adherence to both antihypertensive drug classes and therapy; ARBs followed by ACEIs were associated with the highest class adherence, whereas diuretics and betablockers were associated with the lowest. This confirms the historical findings from many other adherence studies [21, 30, 31] , which has been attributed largely to the more favourable tolerability profile of ARBs and ACEIs compared with other antihypertensive drug classes. However, once switching was considered in measuring adherence to overall antihypertensive drug therapy, ACEIs rather than ARBs had the highest adherence, with beta-blockers no longer having lower adherence compared with diuretics. This implies that all the previous historical findings were indeed biased by not considering switching in measuring adherence, especially given the better tolerability of ARBs compared with others [31] , and hence less switching and better adherence profile of ARBs if switching was not considered. Lower adherence to antihypertensive drug classes and therapy was observed in newly diagnosed hypertensive patients and new antihypertensive drug users. Differences in beliefs, perceptions, and attitudes towards hypertension and antihypertensive drug therapy between incident and prevalent patients could explain the observed disparity in adherence behaviour between these two groups of patients as prevalent patients may have passed the stages of lack of belief in the necessity of treating hypertension [32] . Furthermore, patients' concerns and fears about antihypertensive drugs' adverse effects in the early stages of treatment in the case of incident patients may act as a barrier of adherence to antihypertensive drugs, particularly when patients' hold the belief that a drug's side effects outweigh any potential future benefits [33] . 95% CI, 95% confidence interval; ACEIs, angiotensin converting enzyme inhibitors; ARBs, AT1 blockers; BBs, beta-blockers; CCBs, calcium-channel blockers; CCI, Charlson comorbidity index; NA, not applicable; PDC, proportion days covered.
The current study found a negative association between adherence to antihypertensive drug classes/therapy and presence of comorbidities. It has been reported that patients with no comorbidity were 29% more likely to be adherent compared with those with a high comorbidity score [34] . The negative association between high comorbidity and adherence could be partly explained by comorbidity-related polypharmacy, as additional medications are needed in response to increasing comorbid conditions [35] , which has been found to decrease adherence [36] . Importantly, it appears that this has to exceed a limit before comorbidities have any negative impact of adherence, as it is evident by the fact that both class and therapy adherence were decreasing only for patients with high comorbidity score (CCI ! 2).
In previous studies [7, 37] , switching between antihypertensive drug classes was associated with lower adherence to any antihypertensive drug therapy. This association could be related to many switching-related concerns that would potentially decrease patients' adherence, such as changes in product packaging and tablet appearance [38] and taste [35] , differences in adherence profiles of the various antihypertensive drug classes [8] , and impairing patient's confidence in drug therapy [39] . Furthermore, it has been shown that patients' concerns about switching may produce a nocebo effect (i.e. patients' negative perceptions may cause negative outcomes) [40] .
Demographic factors
Patients' demographics, such as age, sex, and SES, were also significant predicators for antihypertensive drug adherence. Poor SES has been recognized by the WHO as one of the potential factors for patients' nonadherence to antihypertensive drugs [41] . An American cohort study has found that increasing in patients' income quintile, as a proxy for SES, was associated with a 10% increase in the proportion of adherent patients (odds ratio: 1.10, 95% CI: 1.08, 1.12) [34] . Furthermore, a recent retrospective cohort study, which included more than 30 000 adult patients, assessed the association between patients' characteristics and medication adherence across eight diseases, including hypertension and found a higher adherence level in those living in higher SES (lower deprivation) [29] .
Women, in general, have been consistently shown to be less adherent to antihypertensive drug classes [29, 42, 43] . Although similar finding was observed in the current study, importantly this was not the case for adherence to antihypertensive drug therapy as women had higher adherence than men. This could be explained by not allowing/considering switching in measuring adherence to antihypertensive drug classes, especially giving the higher switching rates in women [44] ; that is, once patients have been switched to another antihypertensive drug class they were considered as nonadherent to the initial drug class by definition as they have stopped taking it, but obviously patients have been adherent to the antihypertensive drug therapy overall as they continued to take the new drug class while stopped the initial class. This demonstrates how insights into patients' medication taken behaviours could be biased by purely measuring adherence to antihypertensive drug classes without considering the overall antihypertensive drug therapy, which is more influential on controlling BP.
Strengths and limitations
One of the major strengths of the current study is analysing adherence as a continuous measure by applying an advanced statistical technique (GLM) unlike most of the previous studies [8, 9] which measured and analysed adherence as a binary variable using a nonempirical, arbitrary cut-off point of 80% [8, 14] . Dichotomization of adherence simplifies statistical analysis, presentation, and interpretation of results [45] but incurs several disadvantages. Dichotomization of a continuous variable is often associated with loss of information [46] that can lead to loss of both estimation efficiency and power in hypothesis testing [45, 47] due to a reduction in the number of degrees of freedom [48] . Furthermore, although the 80% cut-off point for optimal adherence has been generally used and linked with clinical outcomes in previous studies, the optimal adherence cut-off point may be higher than 80%, as BP has been found to continuously reduce with increases in adherence from 80 to 100% [49] .
Therefore, the International Society for Pharmaceutical and Outcomes Research [48] has recommended against converting continuous adherence data into binary data. On a related note, previous studies [50, 51] that analysed adherence as a continuous measure have used inappropriate statistical methods to perform the analysis such as ordinary least square (OLS) regression. OLS is considered an inappropriate method because it requires a normally distributed outcome variable that is almost violated by the skewed distribution of the continuous adherence measure.
Another main strength of this study lies in measuring adherence to both antihypertensive drug classes and any antihypertensive drug therapy using a large population dataset of both incident and prevalent hypertensive patients over a long period. Furthermore, applying an advanced statistical technique (GLM) to analyse the association between adherence (as a continuous variable) with a wide range of patient-related factors. This approach has not been observed in previous adherence studies and rendered the findings more generalizable to the wider hypertensive population. For instance, measuring adherence to both antihypertensive drug classes and any antihypertensive drug therapy has increased the applicability of the study findings to the real-world management of hypertension, given the increased proportion of hypertensive patients who are prescribed more than one antihypertensive drug class to control their BP [2] .
Furthermore, failure to allow for switching in measuring class adherence in previous studies implies that the patient failed to take the drug as recommended [9] , which, in fact, may not be the case because patient's switching is often recommended by physicians in response to treatment failure or side effects [13] . Therefore, measuring adherence to any antihypertensive drug therapy (therapy adherence), in this current study, helped us to avoid misunderstanding of patients' medication-taking behaviours toward a particular antihypertensive drug class and provided more insights.
In addition, the model generated from using the GLM method in this study could potentially be applied as a Adherence and patients' characteristics predication tool for identifying patients at risks of poor adherence who could possibly then be targeted for adherence improving interventions; however, this requires further validation and evaluation research.
However, a number of limitations need to be acknowledged. Although a wide range of demographics and clinically related factors were considered in this study, bias due to unmeasured confounders, such as dosing history, cannot be ruled out because of the retrospective nature of the study design. Although some of the antihypertensive drugs could be used to treat other conditions alongside hypertension, the criterion of antihypertensive drugs' prescription date always being on or after the hypertension diagnosis date has ensured that treating hypertension was at least one of the drug's potential indications.
In addition, the CPRD contains only prescribed data; therefore, adherence was measured indirectly by PDC as a proxy, which may lead to further overestimation of medication adherence. Furthermore, overestimation of adherence might have resulted also from excluding patients on multiple therapies at the index date as they might have higher risk of poor adherence.
Another limitation, which applies to any secondary database analysis, includes measuring adherence using secondary databases. This has been validated with other methods of adherence measurement such as electronic devices, patients' self-reports, and pill counts [52, 53] , and no substantial differences between dispensing and prescribing datasets were found [54] . Given the different methods to measure medication adherence using secondary databases, it could be argued that each method may produce different results. However, Hess et al. [55] in their comparison of the various methods of measuring adherence using secondary databases found that all the methods provide comparable values.
Among the adherence measures, medication possession ratio (MPR) and PDC were the best predictors of patients' hospitalizations [56] . PDC is considered preferable than MPR as it provides more conservative estimates of adherence, especially in the presence of therapeutic switching or concurrent drug therapy [57, 58] , even though adherence alone does not provide information on whether patients benefit from the increased use of medicines.
In conclusion, overall adherence to antihypertensive medications was suboptimal among patients with primary hypertension. A set of patient-level factors has been identified as potential determinants for patients' adherence to antihypertensive drugs that would potentially assist to identify patients at risk of poor adherence. Subsequently, those patients can be targeted for adherence improving interventions and/or more intensive follow-up by healthcare professionals to improve their adherence level.
Reviewers' Summary Evaluations
Reviewer 1
Strengths: large database with broad array of antihypertensive drugs.
Weakness: retrospective analysis limits the possibility to draw major conclusions.
Reviewer 2
Today, it is well recognized that persistence of drug therapy is one of the major issue in the long-term management of hypertension. One of the difficulties in clinical practice is the ability to recognize patients at risk of poor adherence. Among the factors that are known to affect long-term adherence, drug classes, the complexity of the therapeutic Adherence and patients' characteristics regimen, comorbidities, age and gender have been identified. In the present study, a large cohort of incident and prevalent patients with hypertension have been studied retrospectively to investigate the impact of drug classes on drug adherence. The authors also investigated the patientrelated risk factors associated with adherence to hypertensive therapy. The assessment was done using the percentage of days covered by the treatment. Although the study was conducted on a large cohort of patients and a more complex statistical analysis was used, the date largely confirm previously published observations. Thus in accordance with several previous publications, blockers of the renin-angiotensin system and particularly angiotensin receptor blockers, were associated with the best adherence and persistence and diuretics with the lowest one.
Comorbidities, being a new patient and the socio-economic status were rather associated with poor adherence to therapy. In this study, men were apparently more adherent than women, a finding that has not unanimously been reported. The major advantage of this study is the large number of patients followed for a long period. One of the limits, which is in part, conditioned by the analysis of a cohort, is the use of the percentage days covered by the therapy as a surrogate marker of adherence and persistence. In fact, having the drug available does by no means prove that drugs were taken correctly. Thus, the high adherence level in this study may be due to the methodology and one can regret the absence of data on the dosing history, which is probably the only pertinent assessment of drug adherence.
